Method
Level · gp.fundamentals.debt_to_revenue
Raw value 208.33% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTARDELYX, INC.'s latest supported as-filed period reports revenue of $120.9M, 23.8% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 208.33% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.01% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -5.29% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 23.77% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 114.98% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -10.28% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 23.8%; Operating margin moved 446 bp higher; Operating income increased 13.7%.
3 evidence-backed componentsResearch & development changed +66.6% from the comparable as-filed period. The change ranks at the 82th percentile of 99 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ARDX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0002093095-26-000007SEC ↗4Aug 25, 2026Period Aug 21, 20260002044416-26-000008SEC ↗4Aug 25, 2026Period Aug 21, 20260001308911-26-000007SEC ↗4Aug 25, 2026Period Aug 21, 20260002088887-26-000007SEC ↗4Aug 25, 2026Period Aug 21, 20260002034148-26-000007SEC ↗4Aug 25, 2026Period Aug 21, 20260001987188-26-000009SEC ↗4Aug 25, 2026Period Aug 21, 20260001869194-26-000011SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 21, 2026Filed Aug 25, 2026 | Hohenleitner SusanChief Financial Officer | Open Market SaleDirect | 1,558 | $4 | $6,009 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Reilly Joseph JamesSee Remarks | Open Market SaleDirect | 2,872 | $4 | $11,077 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Reilly Joseph JamesSee Remarks | Open Market SaleDirect | 1,110 | $4 | $4,281 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Bishop John ESee Remarks | Open Market SaleDirect | 17,281 | $4 | $66,651 | Form 4 ↗ |
| Aug 21, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 21.59% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 12.67% · OPTIONAL
Operating margin changed +446 basis points from the comparable as-filed period. The change ranks at the 4th percentile of 69 prior comparable changes.
Debt changed +25.0% from the comparable as-filed period. The change ranks at the 45th percentile of 31 prior comparable changes.
Revenue changed +23.8% from the comparable as-filed period. The change ranks at the 10th percentile of 69 prior comparable changes.
Inventory / revenue changed -1123 basis points from the comparable as-filed period. The change ranks at the 20th percentile of 15 prior comparable changes.
Stock-based compensation changed +31.1% from the comparable as-filed period. The change ranks at the 49th percentile of 99 prior comparable changes.
Selling, general & administrative changed +20.8% from the comparable as-filed period. The change ranks at the 15th percentile of 26 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001321402-26-000019| Bishop John ESee Remarks |
| Open Market SaleDirect |
| 2,469 |
| $4 |
| $9,523 |
| Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Brady James ParkerChief Human Resources Officer | Open Market SaleDirect | 1,976 | $4 | $7,621 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Brady James ParkerChief Human Resources Officer | Open Market SaleDirect | 13,160 | $4 | $50,757 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Foster Eric DuaneChief Commercial Officer | Open Market SaleDirect | 2,598 | $4 | $10,020 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Foster Eric DuaneChief Commercial Officer | Open Market SaleDirect | 3,389 | $4 | $13,071 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Foster Eric DuaneChief Commercial Officer | Open Market SaleDirect | 2,575 | $4 | $9,932 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Kelliher MikeChief Business Officer | Open Market SaleDirect | 3,104 | $4 | $11,972 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Kelliher MikeChief Business Officer | Open Market SaleDirect | 2,652 | $4 | $10,228 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Kelliher MikeChief Business Officer | Open Market SaleDirect | 2,002 | $4 | $7,722 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Williams Laura AChief Patient Officer | Open Market SaleDirect | 3,486 | $4 | $13,445 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Williams Laura AChief Patient Officer | Open Market SaleDirect | 3,089 | $4 | $11,914 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Williams Laura AChief Patient Officer | Open Market SaleDirect | 2,430 | $4 | $9,372 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Williams Laura AChief Patient Officer | Open Market SaleDirect | 1,734 | $4 | $6,688 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | RAAB MICHAELPresident & CEO | Open Market SaleDirect | 15,009 | $4 | $57,888 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | RAAB MICHAELPresident & CEO | Open Market SaleDirect | 15,976 | $4 | $61,618 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | RAAB MICHAELPresident & CEO | Open Market SaleDirect | 8,411 | $4 | $32,440 | Form 4 ↗ |